Trial Profile
A Phase II/III Adaptive Crossover Study of Intracerebral Transplantation of Neural Stem Cells for the Treatment of Paralysis Due to Ischemic Stroke
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 10 Jan 2018
Price :
$35
*
At a glance
- Drugs NSI 566 (Primary)
- Indications Paralysis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Neuralstem China
- 10 Jan 2018 New trial record